Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Abasaglar Summary of Product Characteristics (SmPC)

How are patients transitioned from another basal insulin to Abasaglar® (insulin glargine)?

If transitioning from another basal insulin to Abasaglar, the recommended initial Abasaglar dose is based on the insulin therapy that is being discontinued.

UK_cFAQ_BIV049_TRANSITION_TABLE
UK_cFAQ_BIV049_TRANSITION_TABLE
en-GB

Detailed Information

If transitioning patients from another basal insulin to Abasaglar therapy, the recommended initial dose of Abasaglar is based on the insulin therapy that is being discontinued (Transitioning From Another Basal Insulin to Abasaglar Therapy).

Reductions in the Abasaglar dose when transitioning from certain insulins will lower the likelihood of hypoglycemia.1,2

Transitioning From Another Basal Insulin to Abasaglar Therapy1,2

If transitioning from…

To…

Then, the recommended initial dose of Abasaglar …

Example

Lantus

Abasaglar

is the same as the Lantus dose.

50 units of Lantus transitions to 50 units of Abasaglar

Toujeo

Abasaglar

is 80% of the Toujeo dose.

50 units of Toujeo transitions to 40 units of Abasaglar

twice-daily NPH insulin

once-daily Abasaglar

is 70%-80% of the total daily NPH insulin dosage.

25 units of NPH insulin every morning and 25 units of NPH insulin every evening, for a daily total of 50 units of NPH insulin, transitions to 35 units (70% of the NPH insulin total daily dose) or 40 units (80% of the NPH insulin total daily dose) of Abasaglar once daily

an intermediate- or long-acting insulin other than Lantus

Abasaglar

may differ from the prior basal insulin dose and other concomitant antihyperglycemic medications may need to be adjusted.

…

Abbreviations: Abasaglar  = Abasaglar® (insulin glargine injection) 100 units/mL; Lantus = Lantus® (insulin glargine injection) 100 units/mL; Toujeo = Toujeo® (insulin glargine injection) 300 units/mL.

References

1Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: May 27, 2021

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

 If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request